2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Epoxide Hydrolase

Epoxide Hydrolase

Epoxide Hydrolase

Related Products

PDF 0.26 MB

Epoxide hydrolases (EH) present in all living organisms. The mammalian soluble epoxide hydrolase (sEH) is a 120 kDa dimer of two identical 62.5 kDa monomers arranged in an anti-parallel fashion. It is mostly expressed in the liver, kidneys, brain, endothelium, and at lesser levels in other tissues. Inflammation and pain are major components of many disease states. Mammalian sEH inhibition reduces blood pressure, inflammation and pain. The anti-inflammatory activities of sEH inhibitors occur in part through the NF-κB mediated down-regulation of COX2 transcription, resulting in lower production of pro-inflammatory prostaglandins such as PGE2 and PGD2.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-173302
    sEH inhibitor-20
    		Inhibitor
    sEH inhibitor-20 is an orally active and metabolically stable sEH inhibitor (IC50: 0.2 nM). sEH inhibitor-20 has significant analgesic and anti-inflammatory activities and is expected to become a potential candidate compound for the study of neuropathic pain.
    sEH inhibitor-20
  • HY-B2117R
    Valpromide (Standard)
    		Inhibitor
    Valpromide (Standard) is the analytical standard of Valpromide (HY-B2117). This product is intended for research and analytical applications. Valpromide is an amide derivative of Valproic acid (HY-10585) and an orally active epoxide hydrolase inhibitor that can cross the blood-brain barrier. Valpromide has antiepileptic, anticonvulsant, and antipsychotic effects. Valpromide also exhibits antiviral activity and can inhibit the reactivation of the EBV lytic cycle.
    Valpromide (Standard)
  • HY-108570R
    AUDA (Standard)
    		Inhibitor
    AUDA (Standard) is the analytical standard of AUDA. This product is intended for research and analytical applications. AUDA (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor with IC50s of 18 and 69 nM for the mouse and human sEH, respectively. AUDA has anti-inflammatory activity.
    AUDA (Standard)
  • HY-126041A
    (±)10(11)-EpDPA
    		Modulator
    (±)10(11)-EpDPA, a docosahexaenoic acid epoxygenase metabolite, acts as a substrate for soluble epoxide hydrolase (sEH) with a Km value of 5.1 µM for human sEH.
    (±)10(11)-EpDPA
  • HY-168211
    LQ-38
    		Inhibitor
    LQ-38 is an orally active inhibitor for soluble epoxide hydrolase (sEH) with an IC50 of 5.2 nM. LQ-38 exhibits anti-inflammatory activity in rat foot edema model and mouse acute pancreatitis model, exhibits analgesic effect in Acetic acid (HY-Y0319)-induced writhing mouse model.
    LQ-38
  • HY-121538S
    CUDA-d11
    		Inhibitor
    CUDA-d11 is deuterium labeled CUDA (HY-121538). CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively. CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease.
    CUDA-d<sub>11</sub>
  • HY-111151R
    AR-9281 (Standard)
    		Inhibitor
    AR-9281 (Standard) is the analytical standard of AR-9281. This product is intended for research and analytical applications. AR9281 (APAU) is a potent, selective and orally active soluble epoxide hydrolase (s-EH) inhibitor. AR-9281 can inhibits human sEH (HsEH) and murine sEH (MsEH) with IC50 values of 13.8 nM and 1.7 nM, respectively. AR9281 can be used for the research of inflammation, hypertension and type 2 diabetes.
    AR-9281 (Standard)
  • HY-159494
    PROTAC sEH-degrader-1
    sEH-degrader-1 (Compound 8) serves as an inhibitor for sEH, with IC50 values of 3.8 nM and 210 nM against hsEH and msEH respectively. sEH-degrader-1 can effectively degrade sEH in mouse liver and brown adipose tissue (Red: UC-1728 (HY-114266), black: linker (HY-W248248), Blue: Thalidomide-5-piperazine (HY-W834174)).
    PROTAC sEH-degrader-1
Cat. No. Product Name / Synonyms Application Reactivity